Data Show Disparities in HMA Use Among Myelodysplastic Syndrome Populations
Findings demonstrate a need to move beyond disease-related factors to address disparities in HMA treatment patterns among those with MDS.
Previous Post
STAT+: Dear Vinay: Please embrace dissent and fade into the background
Next Post
Long-Term Follow-Up Affirms Ivosidenib's Sustained Benefit in IDH1-Mutated AML
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago